Shots:

• The real-world study of Razumab (biosimilar, ranibizumab) vs  Accentrix in patients with DME showed similar effectiveness & safety, baseline characteristics, duration of follow-up & mean number of inj. were similar in both groups
• The primary outcome was the improvement in mean BCVA from baseline to 3mos. then remained stable @6mos. & 1yr. mean reduction in CMT, no differences b/w both groups with no patients suffered drug-related systemic AEs & no differences in visual & anatomical outcomes in treatment-naive patients
• Accentrix is marketed as Lucentis in the US & is commercialized by Genentech. Ranibizumab is an anti-VEGF antibody fragment delivered via IV inj. to treat ophthalmic conditions

Ref: The Center For Biosimilar | Image: Intas